NEWS HIGHLIGHTS
Published Studies Related to Glucotrol (Glipizide)
Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. [2007.03]
OBJECTIVE: To study the effects of pioglitazone, a peroxisome proliferator-activated receptor-y agonist with vascular beneficial effects, and glipizide, an insulin secretagogue, on novel inflammatory vascular risk markers in subjects with and without type 2 diabetes... CONCLUSION: Type 2 diabetes is associated with elevated concentrations of the novel vascular risk marker LpPLA2 and inflammatory risk markers e-selectin and VCAM-1. Neither pioglitazone nor glipizide significantly altered LpPLA2, VCAM-1, or highly sensitive C-reactive protein levels after 12 weeks of therapy. In study subjects with type 2 diabetes, e-selectin concentrations declined significantly with pioglitazone therapy, whereas ICAM-1 concentrations decreased significantly with glipizide therapy.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. [2007.03]
AIM: To compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and inadequate glycaemic control [haemoglobin A(1c) (HbA(1c)) > or = 6.5 and < or = 10%] on metformin monotherapy... CONCLUSIONS: In this study, the addition of sitagliptin compared with glipizide provided similar HbA(1c)-lowering efficacy over 52 weeks in patients on ongoing metformin therapy. Sitagliptin was generally well tolerated, with a lower risk of hypoglycaemia relative to glipizide and with weight loss compared with weight gain with glipizide.
Impact of carriers in oral absorption: Permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide. [2009.06.28]
Carriers may mediate the permeation across enterocytes for drug substances being organic anions. Carrier mediated permeation for the organic anions estrone-3-sulfate (ES) and glipizide across Caco-2 cells were investigated kinetically, and interactions on involved carriers evaluated... Furthermore it is suggested that estrone-3-sulfate may be used to identify compounds which may interact on anionic carriers.
Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide. [2009.02]
The onset of symptomatic hypoglycemia in children with ingestions of second-generation sulfonylureas has never been documented to be later than 21 hours post-ingestion. We report a case with the longest known interval, 45 hours, between ingestion of a sulfonylurea and the onset of hypoglycemia requiring medical intervention...
Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation. [2008.10]
Defining a quantitative and reliable relationship between in vitro drug release and in vivo absorption is highly desired for rational development, optimization, and evaluation of controlled-release dosage forms and manufacturing process. During the development of once daily extended-release (ER) tablet of glipizide, a predictive in vitro drug release method was designed and statistically evaluated using three formulations with varying release rates...
Clinical Trials Related to Glucotrol (Glipizide)
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus [Recruiting]
The purpose of this study is to determine the safety and effectiveness of adding alogliptin
compared to glipizide with metformin in diabetic subjects.
Sitagliptin vs Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency [Recruiting]
The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose
levels in patients with moderate and severe renal insufficiency.
Sitagliptin vs Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease [Recruiting]
The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in
patients with end-stage renal disease on dialysis.
Sitagliptin (MK0431) Versus Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone [Recruiting]
This study will examine the safety and efficacy of the addition of sitagliptin (MK0431)
compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic
control who are taking pioglitazone and metformin.
Standard Medical Management in Secondary Prevention of Ischemic Stroke in China [Recruiting]
|
